Yale University - Section of Cardiovascular Medicine
Date Written: June 26, 2021
Abstract
Myopericarditis has been observed among individuals receiving the BNT162b2-mRNA and mRNA-1273 COVID-19 vaccines.1,2 In this case series, we describe the initial experience with myopericarditis following COVID-19 vaccination across the largest healthcare system in Connecticut.
Note: Funding: None.
Declaration of Interests: Dr. Manan Pareek discloses the following relationships – Advisory Board: AstraZeneca, Janssen-Cilag; Speaker Honorarium: AstraZeneca, Bayer, Boehringer Ingelheim, Janssen-Cilag. Dr. Khera received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (K23HL153775) outside of the submitted work. Dr. Miller discloses the following relationships – Consultant: Eidos, Pfizer, Siemens, Alnylam, Roivant. Grant support: Eidos, Pfizer, Argospect. The other authors report no relevant disclosures.
Ethics Approval Statement: The institutional review board at Yale University approved the study under an expedited review.
Keywords: Adverse Drug Event; Coronavirus; Myocarditis; Pericarditis; Vaccination
Pareek, Manan and Pareek, Manan and Asnes, Jeremy and Baldassarre, Lauren and Casale, Linda and Desai, Nihar and Elder, Robert and Faherty, Erin and Ferguson, Ian and Fishman, Robert and Ghazizadeh, Zaniar and Glick, Laura and Hall, Kevin and Khera, Rohan and Kokkinidis, Damianos and Kwan, Jennifer and O'Marr, Jamieson and Schussheim, Adam and Steele, Jeremy and Tuohy, Edward and Wang, Yanting and Spatz, Erica and Jacoby, Daniel and Miller, Edward, Myopericarditis after Covid-19 Vaccination – a Case Series (June 26, 2021). Available at SSRN: https://ssrn.com/abstract=3874571 or http://dx.doi.org/10.2139/ssrn.3874571
Download This Paper